GALANTAMINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H21NO3
Molecular Weight	287.3535
Optical Activity	( - )
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12C[C@@H](O)C=C[C@]13CCN(C)CC4=CC=C(OC)C(O2)=C34

InChI

InChIKey=ASUTZQLVASHGKV-JDFRZJQESA-N

InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021169s031-021224s029-021615s022lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68005702 | https://www.ncbi.nlm.nih.gov/pubmed/12177686

Galantamine (RAZADYNE®, galantamine hydrobromide) is a benzazepine derived from norbelladine. It is found in Galanthus and other Amaryllidaceae. It is a reversible, competitive acetylcholinesterase inhibitor that is used for the treatment of mild to moderate dementia of the Alzheimer’s type. Although the etiology of cognitive impairment in Alzheimer’s disease is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer’s disease. The degree of this cholinergic loss has been correlated with degree of cognitive impairment and density of amyloid plaques (a neuropathological hallmark of Alzheimer’s disease). While the precise mechanism of galantamine’s (RAZADYNE®, galantamine hydrobromide) action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this mechanism is correct, galantamine’s (RAZADYNE®, galantamine hydrobromide) effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that galantamine (RAZADYNE®, galantamine hydrobromide) alters the course of the underlying dementing process.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Acetylcholinesterase 204 Target ID: CHEMBL220 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021169s031-021224s029-021615s022lbl.pdf	Inhibitor 8146		0.35 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 266 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021169s031-021224s029-021615s022lbl.pdf	Palliative		Approved 8307	RAZADYNE Approved Use Galantamine hydrobromide is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. Launch Date 9.833184E11

C_max

Value	Dose	Co-administered	Analyte	Population
84.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16238894	24 mg single, oral dose: 24 mg route of administration: Oral experiment type: SINGLE co-administered:		GALANTAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1050 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16238894	24 mg single, oral dose: 24 mg route of administration: Oral experiment type: SINGLE co-administered:		GALANTAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
8.53 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16238894	24 mg single, oral dose: 24 mg route of administration: Oral experiment type: SINGLE co-administered:		GALANTAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
82% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021615s021lbl.pdf			GALANTAMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
8 mg 2 times / day steady, oral Dose: 8 mg, 2 times / day Route: oral Route: steady Dose: 8 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23552705/	unhealthy, 90 years n = 1 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 90 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/23552705/	Disc. AE: Nightmares... AEs leading to discontinuation/dose reduction: Nightmares (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/23552705/
32 mg 1 times / day steady, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: steady Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/	unhealthy, adult n = 429 Health Status: unhealthy Condition: Alzheimer's disease Age Group: adult Sex: unknown Population Size: 429 Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/	Other AEs: Nausea, Vomiting... Other AEs: Nausea (42%) Vomiting (21%) Diarrhea (16%) Anorexia (15%) Weight loss (8%) Dizziness (15%) Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/

AEs

AE	Significance	Dose	Population
Nightmares	1 patient Disc. AE	8 mg 2 times / day steady, oral Dose: 8 mg, 2 times / day Route: oral Route: steady Dose: 8 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23552705/	unhealthy, 90 years n = 1 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 90 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/23552705/
Anorexia	15%	32 mg 1 times / day steady, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: steady Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/	unhealthy, adult n = 429 Health Status: unhealthy Condition: Alzheimer's disease Age Group: adult Sex: unknown Population Size: 429 Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/
Dizziness	15%	32 mg 1 times / day steady, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: steady Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/	unhealthy, adult n = 429 Health Status: unhealthy Condition: Alzheimer's disease Age Group: adult Sex: unknown Population Size: 429 Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/
Diarrhea	16%	32 mg 1 times / day steady, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: steady Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/	unhealthy, adult n = 429 Health Status: unhealthy Condition: Alzheimer's disease Age Group: adult Sex: unknown Population Size: 429 Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/
Vomiting	21%	32 mg 1 times / day steady, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: steady Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/	unhealthy, adult n = 429 Health Status: unhealthy Condition: Alzheimer's disease Age Group: adult Sex: unknown Population Size: 429 Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/
Nausea	42%	32 mg 1 times / day steady, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: steady Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/	unhealthy, adult n = 429 Health Status: unhealthy Condition: Alzheimer's disease Age Group: adult Sex: unknown Population Size: 429 Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/
Weight loss	8%	32 mg 1 times / day steady, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: steady Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/	unhealthy, adult n = 429 Health Status: unhealthy Condition: Alzheimer's disease Age Group: adult Sex: unknown Population Size: 429 Sources: https://pubmed.ncbi.nlm.nih.gov/18088197/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670 inhibitor 1532	inhibitor 1695	substrate 1168 inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2A6 670 CYP4A 19 CYP2C 19 CYP2C19 1410 CYP2E1 846 P-gp 1401 Kv1.5 25 BSEP 392 MRP2 363 MRP3 156 MRP4 202 ALDH1 38	UGT1A1 417

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
ALDH1 38	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNTc3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDY1OSJ9fQ%3D%3D	inconclusive [Activation 15.8489 uM]
CYP1A2 1620	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=34, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDY1OSJ9fQ%3D%3D Page: 4, 20, (ClinPharm) 34	no [IC50 >10 uM]
CYP2A6 702	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=34, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDY1OSJ9fQ%3D%3D Page: 4, 20, (ClinPharm) 34	no [IC50 >10 uM]
CYP2C19 1484	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDY1OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 1747	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDY1OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 929	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=34, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDY1OSJ9fQ%3D%3D Page: 4, 20, (ClinPharm) 34	no [IC50 >10 uM]
CYP3A4 1857	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=34, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNjU5In19 Page: 4, 20, (ClinPharm) 34	no [IC50 >10 uM]
BSEP 393	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP2 452	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP3 206	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 235	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=34 Page: 4, 20, (ClinPharm) 34	no
CYP4A 33	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=34 Page: 4, 20, (ClinPharm) 34	no
Kv1.5 40	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/15530663/	no
CYP2C 33	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=34, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=38 Page: 4, 20, (ClinPharm) 34, 38-39	no	no (co-administration study) Comment: Coadministration of Galantamine (multiple doses) had no effect on the pharmacokinetics of R-/S-Warfarin (CYP2C9 substrate) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=34, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=38 Page: 4, 20, (ClinPharm) 34, 38-39
P-gp 1588	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=38, , https://pubmed.ncbi.nlm.nih.gov/19683513/ Page: 4, 20, (ClinPharm) 38, 40	yes [IC50 0.6 uM]	no (co-administration study) Comment: Coadministration of Galantamine (multiple doses) had no effect on the pharmacokinetics of Digoxin (P-gp substrate) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=38, , https://pubmed.ncbi.nlm.nih.gov/19683513/ Page: 4, 20, (ClinPharm) 38, 40

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2D6 1168	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=2, https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=15, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=45, https://pubmed.ncbi.nlm.nih.gov/10634129/ Page: 2, 4, 19-20, (ClinPharm) 15, 38, 42-23, 45	major [Km 187 uM]	yes (co-administration study) Comment: Vmax = 5.2 nmol/mg protein/h (Pharmacogenetics, 9, 661 (1999)); Coadministration (multiple doses) of ketoconazole (strong CYP3A4 inhibitor, CYP2D6 inhibitor) and paroxetin (strong CYP2D6 inhibitor) increased Galantamine AUC by 30% and 40%. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=2, https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=15, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=45, https://pubmed.ncbi.nlm.nih.gov/10634129/ Page: 2, 4, 19-20, (ClinPharm) 15, 38, 42-23, 45
CYP3A4 1670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=2, https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=15, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=38 Page: 2, 4, 19-20, (ClinPharm) 15, 38, 42-44	major	yes (co-administration study) Comment: Coadministration (multiple doses) of ketoconazole (strong CYP3A4 inhibitor, CYP2D6 inhibitor) increased Galantamine AUC by 30%. Coadministration of erythromycin (moderate CYP3A4 inhibitor) increased Galantamine AUC by only 10%. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=2, https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21169lbl.pdf#page=4, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=15, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl_biopharmr.pdf#page=38 Page: 2, 4, 19-20, (ClinPharm) 15, 38, 42-44
UGT1A1 417	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/32520597/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.pmda.go.jp/drugs/2011/P201100024/80015500_23000AMX00426_A100_1.pdf, https://pubmed.ncbi.nlm.nih.gov/22366430/ Page: 17.0

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-5422	http://www.3bsc.com/index/pro_info.php?id=85224
AA Blocks	AA0038PC	https://www.aablocks.com/goods/Goods/detail?id=AA0038PC
AEchem Scientific Corp., USA	AE1-015932	http://www.aechemsc.com/info_products/AE1-015932.php
AHH Chemical co.,ltd	MT-52053	http://www.ahhchemical.com/product/MT-52053.html
AHH Chemical co.,ltd	NP-0540	http://www.ahhchemical.com/product/NP-0540.html
Aaron Chemicals	AR0039H4	http://www.aaronchem.com/357-70-0
Achemtek	0104-018749	http://www.achemtek.com/357-70-0
Acorn PharmaTech	ACN-035451	http://www.acornpharmatech.com/
Ambeed	A697166	https://www.ambeed.com/products/357-70-0.html
Angene	AGN-PC-0RB8F4	http://www.angenechemical.com/productshow/AGN-PC-0RB8F4.html
ApexBio Technology	A3422	http://www.apexbt.com/furagin.html
ApexBio Technology	A1745	http://www.apexbt.com/galanthamine-hbr.html
ApexBio Technology	A3423	http://www.apexbt.com/galanthamine.html
Aurora Fine Chemicals LLC	K04.008.117	http://online.aurorafinechemicals.com/info?ID=K04.008.117
Aurum Pharmatech LLC	W-5162	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5162
AvaChem Scientific	1543B	http://www.avachem.com/productSearch.asp?1543B
BLD Pharm	BD8903	http://www.bldpharm.com/products/357-70-0.html
CSNpharm	CSN19397	https://www.csnpharm.com/products/galanthamine.html
Chem Scene	CS-1217	http://www.chemscene.com/357-70-0.html
ChemFaces	CFN90743	http://www.chemfaces.com/natural/Galantamine-CFN90743.html
ChemMol	30107850	http://www.chemmol.com/chemmol/30107850.html
Chemenu	CM124392	http://www.chemenu.com/products/CM124392
Chemspace	CSSB00025726588	https://chem-space.com/CSSB00025726588
Clearsynth	CS-O-01567	http://www.clearsynth.com/en/CSO01567.html
DC Chemicals	DCJ-030	http://www.dcchemicals.com//product_show-Galanthamine.html
Lab Network	LN01094084	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01094084
MedChem Express	HY-76299	https://www.medchemexpress.com/Galanthamine.html
MuseChem	I003311	https://www.musechem.com/product/I003311.html
OChem	3076	http://www.ocheminc.com/index.php?act=psearch&pid=357G700
Parchem	29043	http://www.parchem.com/chemical-supplier-distributor/Galantamine-019043.aspx
Parchem	29044	http://www.parchem.com/chemical-supplier-distributor/Galantamine-Hydrobromide-019044.aspx
Parchem	29045	http://www.parchem.com/chemical-supplier-distributor/Galantamine-Hydrobromide-019045.aspx
Parchem	29046	http://www.parchem.com/chemical-supplier-distributor/Galanthamine-019046.aspx
Selleck Chemicals	S3866	http://www.selleckchem.com/products/galanthamine.html
Smolecule	S528644	http://www.smolecule.com/products/s528644
Smolecule	S748849	https://www.smolecule.com/products/s748849
THE BioTek	bt-268966	https://www.thebiotek.com/product/inhibitors/bt-268966
TripleBond	CG0028	http://www.triplebond-canada.com/prod/1357/
abcr GmbH	AB494689	http://www.abcr.com/shop/en/AB494689
eNovation Chemicals	D582252	https://www.enovationchem.com/ProductDetails.asp?ProductID=D582252
eNovation Chemicals	Y1043960	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1043960
iChemical	EBD2184763	http://www.ichemical.com/products/357-70-0.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-7156449246	https://mcule.com/MCULE-7156449246/
mcule	MCULE-7226205054	https://mcule.com/MCULE-7226205054/

PubMed

Title	Date	PubMed
[Perspectives for drug treatment in Alzheimer's disease].	2001 Dec	11937989
Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy.	2002	12456064
Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.	2002	12381243
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.	2002	12162759
[New theory! Galantamine and nicotinic-cholinergic transmission].	2002	12162069
Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.	2002	12145455
Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.	2002	12141890
Galantamine for Alzheimer's disease.	2002	12137632
Cholinergic medication for neuroleptic-induced tardive dyskinesia.	2002	12137608
A non-cholinergic, trophic action of acetylcholinesterase on hippocampal neurones in vitro: molecular mechanisms.	2002	12031351
Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.	2002 Apr	11936568
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.	2002 Apr 13	11965273
Galantamine for vascular dementia: some answers, some questions.	2002 Apr 13	11965268
To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?	2002 Aug 19	12184819
An efficient enantioselective synthesis of (-)-galanthamine.	2002 Aug 2	12203489
Unconventional ligands and modulators of nicotinic receptors.	2002 Dec	12436414
New drugs 2002, part 1.	2002 Jan	12352750
Medical treatment of Alzheimer's disease: past, present, and future.	2002 Jul	12182092
Galanthamine as bis-functional ligand for the acetylcholinesterase.	2002 Jun	12140604
Switching cholinesterase inhibitors in patients with Alzheimer's disease.	2002 Jun	12139369
Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.	2002 Jun	12139368
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.	2002 Jun	12139367
The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.	2002 Jun	12139365
[Nicotinic Receptor, galantamine and Alzheimer disease].	2002 Jun 1-15	12134305
Pharmacologic treatments of dementia.	2002 May	12171061
The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.	2002 May	11961141
The metabolism and excretion of galantamine in rats, dogs, and humans.	2002 May	11950787
[Latest therapies for treating dementia].	2002 May 15	12031225
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.	2002 Nov	12359103
[Rivastigmine: a review of its clinical effectiveness].	2002 Nov 1-15	12436385
[Treatment of Alzheimer's disease].	2002 Nov 1-15	12436384
The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease.	2002 Nov 15	12417371
Treatment options: the latest evidence with galantamine (Reminyl).	2002 Nov 15	12417370
Use of galantamine to treat vascular dementia.	2002 Nov 9	12433549
Use of galantamine to treat vascular dementia.	2002 Nov 9	12433548
Galantamine improved cognition and global functioning in vascular dementia or Alzheimer disease with cerebrovascular disease.	2002 Nov-Dec	12418842
Cognitive pharmacotherapy of Alzheimer's disease and other dementias.	2002 Oct	12420649
[Galantamine: a novel cholinergic agent for Alzheimer's disease].	2002 Oct	12396973
The impact of journal advertisements on prescribers of cholinesterase inhibitors.	2002 Oct	12325061
Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts.	2002 Oct 11	12270757
A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat.	2002 Oct 25	12398920
The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies.	2002 Oct-Nov	12450245
Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months.	2002 Sep	12296613
Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine.	2002 Sep	12220392
Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects.	2002 Sep	12211216
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.	2002 Sep	12169216
Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block.	2002 Sep 16	12182861
Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia.	2002 Sep-Oct	12410061
Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.	2002 Summer	12391943
Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.	2002 Summer	12177686

Patents

Sample Use Guides

In Vivo Use Guide

The recommended starting dosage of RAZADYNE® tablets is 4 mg twice a day (8 mg/day). The dosage should be increased to the initial maintenance dosage of 8 mg twice a day (16 mg/day) after a minimum of 4 weeks. A further increase to 12 mg twice a day (24 mg/day) should be attempted after a minimum of 4 weeks at 8 mg twice a day (16 mg/day). Dosage increases should be based upon assessment of clinical benefit and tolerability of the previous dose.

Route of Administration: Oral

In Vitro Use Guide

Galanthamine was evaluated as inhibitor of human acetylcholinesterase activity from samples of postmortem human brain, fresh brain cortex biopsies and human erythrocytes. The respective galanthamine concentration exerting a half maximal effect (IC50) on acetylcholinesterase in postmortem human brain frontal cortex was 3.2 uM versus 2.8 uM in the hippocampus region. In addition, galanthamine was 10-fold less potent in inhibiting the enzyme activity from human brain that from human erythrocytes.

Name

Type

Language

GALANTAMINE

Official Name

English

6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)

Common Name

English

GALANTAMINE [USAN]

Common Name

English

galantamine [INN]

Common Name

English

(-)-GALANTHAMINE

Common Name

English

Galantamine [WHO-DD]

Common Name

English

(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol

Common Name

English

GALANTAMINE [MI]

Common Name

English

GALANTHAMINE

Common Name

English

(-)-GALANTAMINE

Common Name

English

NSC-100058

Code

English

GALANTAMINE [VANDF]

Common Name

English

GALANTAMINE [HSDB]

Common Name

English

Classification Tree Code System Code

DSLD

4148 (Number of products:1)

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

NCI_THESAURUS

C47792

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

NDF-RT

N0000175723

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

NDF-RT

N0000000177

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

LIVERTOX

NBK548544

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

WHO-ATC

N06DA04

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

WHO-VATC

QN06DA04

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

Code System Code Type Description

RXCUI

4637

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

RxNorm

DAILYMED

0D3Q044KCA

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

DRUG BANK

DB00674

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

EPA CompTox

DTXSID2045606

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

NCI_THESAURUS

C65797

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

INN

1392

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

FDA UNII

0D3Q044KCA

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

DRUG CENTRAL

1272

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

NSC

100058

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

MERCK INDEX

M5640

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

Merck Index

IUPHAR

6693

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

MESH

D005702

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

WIKIPEDIA

GALANTAMINE

Created by admin on Fri Dec 16 20:11:51 UTC 2022 , Edited by admin on Fri Dec 16 20:11:51 UTC 2022

PRIMARY

USAN

MM-35

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

CAS

357-70-0

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

PUBCHEM

9651

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

HSDB

7361

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

ChEMBL

CHEMBL659

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

EVMPD

SUB07870MIG

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

CHEBI

42944

Created by admin on Fri Dec 16 20:11:50 UTC 2022 , Edited by admin on Fri Dec 16 20:11:50 UTC 2022

PRIMARY

ACTIVE MOIETY


					0D3Q044KCA

GALANTAMINE

METABOLITE (PARENT)


					5BRJ2JZF7W

EPIGALANTAMINE N-OXIDE

METABOLITE (PARENT)


					2BPQ4IVQ21

N-DESMETHYLGALANTAMINE

METABOLITE (PARENT)


					S6AF61T5WO

GALANTAMINE N-OXIDE

METABOLITE (PARENT)


					TN3JC254YN

N-DESMETHYL-EPIGALANTAMINE

METABOLITE (PARENT)


					L7ZOW3CZ7W

O-DESMETHYLGALANTAMINE

METABOLITE (PARENT)


					38CR9WB857

NARWEDINE

METABOLITE (PARENT)


					6UF6U93C58

O-DESMETHYL GALANTAMINE O-SULFATE

METABOLITE (PARENT)


					CGC7CQT3LU

O-DESMETHYL-EPIGALANTAMINE GLUCURONIDE

METABOLITE (PARENT)


					P5ATS8V989

EPIGALANTAMINE

METABOLITE (PARENT)


					U7GAV7A4EL

GALANTAMINE 3-.BETA.-D-GLUCURONIDE

METABOLITE (PARENT)


					KHF25P7J35

O-DESMETHYL-EPIGALANTAMINE

METABOLITE (PARENT)


					XX89R6HA54

O-DESMETHYL-GALANTAMINE GLUCURONIDE

PRODRUG (METABOLITE ACTIVE)


					XOI2Q0ZF7G

BENZGALANTAMINE

SALT/SOLVATE (PARENT)


					HV8VV786RM

GALANTAMINE HYDROCHLORIDE

SALT/SOLVATE (PARENT)


					MJ4PTD2VVW

GALANTAMINE HYDROBROMIDE

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021169s031-021224s029-021615s022lbl.pdfCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68005702 | https://www.ncbi.nlm.nih.gov/pubmed/12177686

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021169s031-021224s029-021615s022lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68005702 | https://www.ncbi.nlm.nih.gov/pubmed/12177686

C_max

T_1/2

F_unbound

Drug as perpetrator